Immediate slots available banner

Immediate slots available banner


T cells are smart: naturally detecting and eliminating tumor cells—but cancer can evade the body’s defenses.

Breyanzi® is your patient’s T cells made smarter: CAR T cells engineered to target and kill CD19-expressing B cells.

At the first sign of 1L LBCL failure,
Reach for a cure with Breyanzi2,3

Now FDA-approved harmonized Breyanzi specifications:
reduced out-of-specification rate will deliver timely access for more patients5

Retrospective analysis demonstrated that if these new specifications were applied to prior commercial product, the manufacturing success rate would be5:

    • 93% manufacturing success rate in 2L LBCL
    • 91% manufacturing success rate in 3L+ LBCL
Immediate slot availability for Breyanzi

Increased manufacturing capacity means you can schedule your patient’s one-time infusion* of Breyanzi without the wait.2

Lisocabtagene maraleucel (Breyanzi) is recommended by National Comprehensive Cancer Network® (NCCN®)6

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

*Treatment process can take approximately 2 to 3 months and includes leukapheresis, manufacturing, administration, and adverse event monitoring.2
Lots manufactured between Q1 2021 and Q1 2024.5
Manufacturing success rate is calculated as commercial products successfully manufactured from patients apheresed.5

1L, first-line; 2L, second-line; 3L, third-line; CAR, chimeric antigen receptor; CI, confidence interval; LBCL, large B-cell lymphoma; mEFS, median event-free survival; NCCN, National Comprehensive Cancer Network® (NCCN®); NR, not reached; R/R, relapsed or refractory.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.